<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04280848</url>
  </required_header>
  <id_info>
    <org_study_id>N/2013/67</org_study_id>
    <nct_id>NCT04280848</nct_id>
  </id_info>
  <brief_title>Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma</brief_title>
  <acronym>UCPVax-Glio</acronym>
  <official_title>Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glioblastoma (GBM) is the most frequent primary brain tumor and the brain tumor with the&#xD;
      poorest prognosis. The current treatment relies on surgical resection of gross tumor followed&#xD;
      by radiochemotherapy and adjuvant therapy with temozolomide.&#xD;
&#xD;
      After such therapy, most patients experiment recurrence and few therapeutic option are&#xD;
      available. Despite such therapies, median survival only reaches around fifteen months.&#xD;
&#xD;
      There is a strong rational to develop telomerase vaccine in GBM. Telomerase (TERT) is a major&#xD;
      oncogene, particularly in primary brain tumors 24. Alterations in TERT are very frequent in&#xD;
      central nervous system tumors, seen most commonly in gliomas25. Mutations in the TERT&#xD;
      promoter are found in approximately 80% of primary glioblastoma (GBM). These findings&#xD;
      strongly support the rational to develop vaccine targeting telomerase in GBM.&#xD;
&#xD;
      The aim of this project is to evaluate UCPVax treatment in glioblastoma. UCPVax is a&#xD;
      therapeutic anti-cancer vaccine based on the telomerase-derived helper peptides designed to&#xD;
      induce strong TH1 CD4 T cell responses in cancer patients (NCT02818426).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 26, 2020</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>at day 60</time_frame>
    <description>Anti-TERT specific T cell responses measured in peripheral blood using IFN-gamma ELISPOT</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>UCPVax vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UCPVax is a therapeutic vaccine derived from telomerase combined with Montanide ISA51 VG as adjuvant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UCPVax</intervention_name>
    <description>The UCPVax vaccination protocol will start at least one month after glioblastoma patients have completed the concomitant radiochemotherapy (Radiotherapy + Temozolomide RT/TMZ), without the 6 additional monthly cures of temozolomide, with a maximum of 45 days.&#xD;
UCPVax vaccine will be emulsified in Montanide ISA 51 and injected subcutaneously at days 1, 8, 15, 29, 36 and 43 (priming phase) following by boost vaccination one month after the last injection and then every 8 weeks for 12 months maximum.</description>
    <arm_group_label>UCPVax vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients, age ≥ 18 and ≤ 75 years old&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Histologically confirmed glioblastoma&#xD;
&#xD;
          -  Patient with unmethylated MGMT (Methyl guanine methyl transferase) status&#xD;
&#xD;
          -  Patients previously pre-treated with standard radiochemotherapy (without the&#xD;
             additional cures of temozolomide.)&#xD;
&#xD;
          -  Karnofsky Performance status ≥ 70%&#xD;
&#xD;
          -  Life-expectancy &gt; 3 months&#xD;
&#xD;
          -  Adequate hematological, hepatic, and renal function.&#xD;
&#xD;
          -  Females must be using highly effective contraceptive measures , and have a negative&#xD;
             pregnancy test prior to the start of dosing if of childbearing potential, or must have&#xD;
             evidence of non-childbearing potential.&#xD;
&#xD;
        Females of childbearing potential should use reliable methods of contraception from the&#xD;
        time of the screening until 5 weeks after discontinuing study treatment.&#xD;
&#xD;
        Male patients with a female partner of childbearing potential should be willing to use&#xD;
        barrier contraception during the study and for 5 months following discontinuation of study&#xD;
        drug. Patients should refrain from donating sperm from the start of dosing until 5 months&#xD;
        after discontinuing study treatment.&#xD;
&#xD;
        - Affiliation to French social security or receiving such a regime.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of known extracranial metastatic or leptomeningeal disease Glioblastoma with&#xD;
             mutated IDH1 (assessed by Immunohistochemistry)&#xD;
&#xD;
          -  Current or recent treatment with another investigational drug&#xD;
&#xD;
          -  Carmustine implant during surgery&#xD;
&#xD;
          -  History of autoimmune diseases (lupus, rheumatoid arthritis, inflammatory bowel&#xD;
             disease…)&#xD;
&#xD;
          -  Prohibited medications:&#xD;
&#xD;
               1. Chronic treatment with immunosuppressive drugs&#xD;
&#xD;
               2. Ongoing requirement for supraphysiologic steroid defined as &gt;10 mg prednisone&#xD;
                  daily (or equivalent)&#xD;
&#xD;
               3. Treatment with therapeutic oral or IV antibiotics within 4 weeks prior to&#xD;
                  enrollment. Patients receiving prophylactic antibiotics (e.g., to prevent a&#xD;
                  urinary tract infection or pulmonary disease) are eligible for the study&#xD;
&#xD;
          -  Known positive serology for Human Immunodeficiency Virus (HIV) or Hepatitis C virus&#xD;
             (HCV); presence in the serum of the antigens HBs&#xD;
&#xD;
          -  Non-hematologic toxicities Grade &gt;1 severity (or, at the investigator's discretion,&#xD;
             Grade &gt;2 if not considered a safety risk for the patient).&#xD;
&#xD;
          -  Patient with intra-alveolar hemorrhage, pulmonary fibrosis, or uncontrolled asthma, or&#xD;
             chronic obstructive disease (COPD), defined as at least 1 hospitalization within 4&#xD;
             months prior to enrollment or as at least 3 exacerbations during the last year prior&#xD;
             to enrollment Hospitalization for cardiovascular or pulmonary disease within 4 weeks&#xD;
             prior to enrollment.&#xD;
&#xD;
          -  Patients with LEVF&lt;40%&#xD;
&#xD;
          -  Participation in a clinical study with an investigational product within 4 weeks prior&#xD;
             to the start of the study treatment or patient in the exclusion period of a previous&#xD;
             clinical trial.&#xD;
&#xD;
          -  Pregnancy or lactating patients.&#xD;
&#xD;
          -  Patients with any severe/uncontrolled inter current illness, significant co morbid or&#xD;
             psychiatric conditions that in the opinion of the investigator would impair study&#xD;
             participation or cooperation.&#xD;
&#xD;
          -  Patients under guardianship, curatorship or under the protection of justice.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clotilde VERLUT, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Besançon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier ADOTEVI, Pr</last_name>
    <phone>+33381668166</phone>
    <email>olivier.adotevi@univ-fcomte.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clotilde VERLUT, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Clotilde VERLUT, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charlotte BRONNIMANN, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François GHIRINGHELLI, Pr</last_name>
    </contact>
    <investigator>
      <last_name>François GHIRINGHELLI, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine CARPENTIER, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Antoine CARPENTIER, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 17, 2020</study_first_submitted>
  <study_first_submitted_qc>February 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2020</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

